Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?

Abstract.

Objective: To determine the pharmacokinetic profile of ciprofloxacin 20 mg/kg per day (10 mg/kg administered intravenously 12 hourly) in paediatric patients with severe sepsis. Design: Open and prospective. Setting: Tertiary referral multi-disciplinary ICU. Patients: Twenty patients (two groups – group A: 3 months–1 year; group B 1–5 years). Interventions: Timed blood samples were taken for pharmacokinetics after the first dose (D₀), as well as day 2 (D₂) and then between days 6–8. Measurements and results: Ciprofloxacin serum levels were measured by high performance liquid chromatograghy. Demographic and clinical data and all adverse events were noted. Standard pharmacokinetic variables were calculated by non-compartmental methods. Peak concentrations (C_max) for group A were D₀ 6.1±1.2 mg/l, D₂ 9.0±1.8 mg/l and D₇ 5.8±1.3 mg/l and, for group B, 7.4±1.3 mg/l, 7.8±1.6 mg/l and 6.4±1.3 mg/l, respectively, for the study periods. Concentration 12 h after the start of infusion (C_min) for all periods were 0.2 mg/l or less. Areas under the curve (AUC, 12 h) were group A: 15.6±1.3, 19.2±1.63 and 14.1±1.4 mg/h per l, and group B: 15.9±1.3, 18.0±1.7 and 13.2±1.26 mg/h per l. One patient presenting with seizures, initially controlled, had another convulsion and a further patient developed seizures whilst on ciprofloxacin. C_max in these patients were higher than the average C_max. The convulsions of both patients were easily controlled. No other drug-related serious adverse events occurred. No arthropathy was noted. Three patients died of their underlying disease. Conclusions: There was no accumulation of drug even after 7 days of administration. Our C_max and AUC were lower than that achieved in a similar adult pharmacokinetic study. To achieve end points of area under the inhibitory curve (AUIC) of 100–150 mg/h per l, 10 mg/kg ciprofloxacin eight hourly would be required for some resistant ICU organisms.